Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...